LABP Landos Biopharma, Inc.

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oral therapeutics for patients with autoimmune diseases. Our pipeline, which currently contains seven preclinical and clinical product candidates, leverages our LANCE precision medicine platform to optimally identify novel immunometabolic targets and address a wide range of disease indications.

$0.26  +0.00 (0.70%)
As of 03/21/2023 16:00:00 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/04/2021
Outstanding shares:  40,254,890
Average volume:  507,269
Market cap:   $15,087,533
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BMVHFM0

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%